Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia

Schilit, Sara; Benzeroual, Kenza E.

doi:10.1016/j.clinthera.2009.11.024

Cited by 58 publications

(41 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Silodosin is a new alpha1A-blocker and has been approved by the US Food and Drug Administration for the treatment of BPH since October 2008. 23 The previous meta-analysis showed that Silodosin is an effective therapy for lower urinary tract symptoms in men with BPH and is not inferior to 0.2 mg tamsulosin. 24 It is reported that ureteral contraction was regulated mainly by alpha-1A adrenoceptors in the hamster ureter.…”

Section: Discussionmentioning

confidence: 99%

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

To evaluate the efficacy of Silodosin as a medical expulsive therapy of ureteral stones, we searched PubMed, EMBASE, the Cochrane Library, and CBM up to June 2015. All randomized controlled trials (RCTs) were identified in which patients were randomized to receive Silodosin versus placebo or other therapies for ureteral stones. Outcome measures assessed were overall stone expulsion rate (primary) and expulsion time, analgesics times, and the incidence of additional treatment and regarding treatment complications (secondary). Two authors independently assessed study quality and extracted data. All data were analyzed using RevMan 5.3. Seven RCTs with a total of 1035 patients met the inclusion criteria. The pooled meta-analysis showed a significant improvement in stone clearance with Silodosin (Silodosin versus placebo, OR ¼1.69, 95% CI [1.19-2.40], p ¼ 0.003; Silodosin versus tamsulosin, OR ¼2.82, 95% CI [1.79-4.44], p < 0.00001). According to the size and location of ureteral stone, the pooling effects of Silodosin were analyzed, with a meaningful expulsion rate in distal ureteral stone when the size was 5-10 mm. In addition, a shorter expulsion time, fewer analgesics times, and additional treatments were observed. The common side effect was retrograde ejaculation. In summary, Silodosin appears to be more effective than either placebo or tamsulosin. Within the limits of available data, highquality multicenter RCTs are needed to thoroughly evaluate the outcome in the future. ARTICLE HISTORY

show abstract

Section: Discussionmentioning

confidence: 99%

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…(24) The incidence of orthostatic hypotension with silodosin has been reported to be <3%. (25) Results from our study shows retrograde ejaculation in 5 (19.2%) patients treated with silodosin and none in tamsulosin group. The incidence of side effects related to peripheral vasodilation in tamsulosin group is 15 (30%) and silodosin group is 8 (16%), which is in accordance with most of the published studies.…”

Section: Discussionmentioning

confidence: 87%

A Prospective Study Comparing Tamsulosin and Silodosin in Medical Expulsive Therapy for Lower Ureteric Stones

Reddy¹,

Prathvi²,

Kulshreshtha³

et al. 2016

jemds

View full text Add to dashboard Cite

The urinary stone disease is one of the most common afflictions of the modern society and it has been described since antiquity with the westernization of global culture. The efficacy of mini-invasive therapies, such as Extracorporeal Shock Wave Lithotripsy [ESWL] and ureteroscopy are not risk free, are problematic and are quite expensive. Recently, the use of watchful waiting approach has been extended by using Pharmacotherapy. This can reduce symptoms and facilitate stone expulsion. MATERIALS AND METHODSThis prospective randomised study was conducted between September 2015 and May 2016 at Rajarajeshwari Medical College and Hospital, Bangalore. The cohort comprised 100 adult patients (54 men and 46 women) who presented with a symptomatic, unilateral, single, uncomplicated lower ureteric stone of ≤ 10 mm. Patients were randomized into two equal groups, 50 (50%) patients received a daily single dose of tamsulosin 0.4 mg for 28 days and 50 (50%) patients received a daily single dose of silodosin 8 mg for 28 days. Both groups were compared in terms of patient's demographics, socioeconomic status, stone size and side, type of MET, stone expulsion rate, stone expulsion time, number of pain episodes, need for analgesics use and incidence of side effects. Subgroup analysis was performed according to stone size ≤ or > 5 mm. RESULTSNo significant differences among the two groups for patient's age, gender, stone side and stone size. Spontaneous stone expulsion rate within 28 days was observed in 44 (88%) patients in the tamsulosin group and in 45 (90%) patients in the silodosin group without statistically significant differences. There were no statistically significant differences observed in terms of mean expulsion time, mean number of pain episodes and need for analgesics. Retrograde ejaculation was significantly higher in the silodosin arm, while the incidence of side effects related to peripheral vasodilation were higher in the tamsulosin arm, but it was statistically insignificant. CONCLUSIONTamsulosin and silodosin are equally effective as MET for distal ureteric stones sized 10 mm or smaller. MET with silodosin is associated with a lower incidence of side effects related to peripheral vasodilation, but a higher incidence of retrograde ejaculation when compared to tamsulosin. However, a multicentre study on a larger scale is needed to evaluate the current medicines. KEYWORDSTamsulosin, Silodosin, Stone Expulsion Rate, Medical Expulsion Therapy (MET). Financial or Other, Competing Interest: None. Submission 18-06-2016, Peer Review 13-07-2016, Acceptance 18-07-2016, Published 25-07-2016. Corresponding Author: Dr. Sreedhar Reddy, Professor and HOD, Department of Urology Raja Rajeshwari Medical College and Hospital, Bangalore. E-mail: urologyreddy@yahoo.com DOI: 10.14260/jemds/2016 Nevertheless these techniques are not risk free, are problematic and are quite expensive. (4) Recently, the use of watchful waiting approach has been extended by using Pharmacotherapy. This can reduce symptoms and facilitat...

show abstract

“…Silodosin is a new alpha 1A -blocker and has been approved by the US Food and Drug Administration for the treatment of BPH since October 2008. 22 However, the efficacy and safety of silodosin were unclear. Therefore, we combined subject searching with random searching to obtain relevant articles and used meta-analysis to evaluate the efficacy and safety of silodosin for the treatment of LUTS/BPH.…”

Section: Discussionmentioning

confidence: 99%

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Ding¹,

Du²,

Hou³

et al. 2012

Asian J Androl

View full text Add to dashboard Cite

The aim of this study was to systematically review the evidence on the efficacy and safety of silodosin treatments on lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH) from randomized controlled trials. We searched PubMed (1966-December 2011), Embase (1974-December 2011 and the Cochrane Library Database (2011, Issue 12). The assessed outcome measures were the change from baseline for the International Prostate Symptom Score (IPSS), quality of life (QoL) score, peak urine maximum flow rate (Q max ), QoL related to urinary symptoms and adverse effects. Two authors independently assessed the study quality and extracted data. All data were analysed using RevMan 5.1. The meta-analysis included four randomized controlled trials with a total of 2504 patients. The study durations were each 12 weeks. At the follow-up end points, the pooled results showed that the change from baseline for the silodosin group was significantly higher than the placebo group for the IPSS, QoL score and Q max (mean difference (MD)522.78, P,0.00001; MD520.42, P50.004; MD51.17, P,0.00001,respectively) and patients felt more satisfied with QoL related to urinary symptoms in the silodosin group than the placebo group. Ejaculation disorder was the most commonly reported adverse effect. The pooled results also showed that the silodosin group was superior to the 0.2 mg tamsulosin group with respect to the IPSS and QoL score (IPSS: MD521.14, P50.02; QoL score: MD520.26, P50.02) and inferior to the 0.2 mg tamsulosin group with respect to Q max (MD520.85, P50.01). In contrast, there was no significant difference in the incidence of ejaculation disorder and dizziness between the silodosin and 0.2 mg tamsulosin groups. The current meta-analysis suggested that silodosin is an effective therapy for LUTS in men with BPH and is not inferior to 0.2 mg tamsulosin. Keywords: benign prostatic hyperplasia (BPH); KMD-3213; lower urinary tract symptoms (LUTS); silodosin; tamsulosin; systematic review; meta-analysis INTRODUCTION Histologically, benign prostatic hyperplasia (BPH) is a non-malignant enlargement of the prostate caused by cellular hyperplasia of both glandular and stromal elements.1 However, it is clinically characterised by lower urinary tract symptoms (LUTS) (urinary frequency, urgency, a weak and intermittent stream, the need to strain, a sense of incomplete emptying and nocturia), and can lead to complications, including acute urinary retention.2 The development of human BPH correlates with increasing age, 3 and LUTS are fairly common after the age of 50 years. 4 As is well known, the treatment options include alpha-blockers, five alpha-reductase inhibitors, transurethral resection of the prostate, transurethral microwave thermotherapy and herbal treatments (saw palmetto and b-sitosterol plant extracts). According to the EAU 2011 guidelines, alpha-blockers are currently the preferred first-line therapy for all men with moderate or severe LUTS/BPH.5 Alpha-blockers for BPH include alfuzosin, prazosin, doxazosin, tamsul...

show abstract

Silodosin: A selective α1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia

Cited by 58 publications

References 25 publications

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis

A Prospective Study Comparing Tamsulosin and Silodosin in Medical Expulsive Therapy for Lower Ureteric Stones

Silodosin is effective for treatment of LUTS in men with BPH: a systematic review

Contact Info

Product

Resources

About